Barely Significant
← all excerpts

Feasibility of <i>TP53</i>-Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS.

Cancers (Basel) · 2026 · PMC13072404 · PMID 41976325

Europe PMCDOI
1
hedged sentence
0.0620
closest p · 1.2× alpha
0.0620
boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)
Baseline ctDNA positivity was strongly associated with poorer outcomes: patients with detectable ctDNA at M0 had significantly reduced recurrence-free survival (2-year RFS: 18% vs 60%, log-rank p = 0.010) and showed a trend toward inferior overall survival (2-year OS: 40% vs 78%, log-rank p = 0.062).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.